PITTSBURGH, April 3, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that the company has been selected to present at the annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Kenneth
CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of A? oligomers to the receptor complex. The molecule was designed by Cognition’s scientific team, led by Susan Catalano, Ph.D., to target, displace and clear the toxic beta amyloid oligomers that cause Alzheimer’s disease. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s ongoing Study COG0102, patients with mild-to-moderate Alzheimer’s disease are being randomized to one of two doses of CT1812 (280mg patients or 560mg) or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Cognition has previously conducted single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Additional information about Cognition may be found online at http://www.cogrx.com.